Abbott Kicks Off Diabetes Control For Life Program In China
This article was originally published in PharmAsia News
To tap the growing diabetes market in China, multinational pharmaceutical companies are competing to find new ways to educate consumers and advertise their products. At a recent seminar on the progress of international diabetes nutrition therapy, Abbott introduced its new diabetes management plan - Diabetes Control for Life. The free 24-week diabetes management program allows diabetics to better control their blood glucose and helps them fight the disease through a healthy lifestyle. The DCFL plan has been launched in the U.S. and China experts are conducting a comparative study. (Click here for more - Chinese Language)
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.